IP Library › Granted Patent US 12,644,101
Granted Patent B2
US 12,644,101 · App. 18/484,856 · Granted Jun 2, 2026

Adeno-associated virus (AAV) clade F vector and uses therefor

Inventors: James M. Wilson (Philadelphia, PA); Qiang Wang (Philadelphia, PA); April Tepe (Laurel, MD); Kevin Turner (Newtown Square, PA)
Assignee: The Trustees of the University of Pennsylvania
C12N7/00A61K35/761C07K14/005C07K16/32C12N2750/14121C12N2750/14122C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,644,101
App. No.
18/484,856
Granted
Jun 2, 2026
Kind
B2
Abstract

A recombinant adeno-associated virus (rAAV) vector comprising an AAVhu68 capsid produced in a production system comprising a nucleotide sequence of SEQ ID NO: 1, or a sequence at least 75% identical thereto which encodes SEQ ID NO:2. The AAVhu68 capsid comprises subpopulations of highly deamidated asparagine residues in asparagine-glycine pairs in the amino acid sequence of SEQ ID NO: 2. Also provided are compositions containing the rAAV and uses thereof. Additionally, rAAV having an engineered AAV capsid comprising at least one subpopulation of vp1 or vp2 proteins having a Val at amino acid position 157 with reference to the AAVhu68 vp1 numbering are provided.

Claims (18)

1 . A method for purifying a rAAVhu68 vector comprising:

(a) culturing a packaging host cell comprising

(i) an AAVhu68 capsid nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:2 operably linked to regulatory sequences which direct expression of AAVhu68 VP1 capsid proteins, AAVhu68 VP2 capsid proteins and AAVhu68 VP3 capsid proteins, wherein said capsid proteins which assemble into an AAVhu68 capsid in the cells of the culture;

(ii) a nucleic acid molecule comprising a vector genome for packaging into the AAVhu68 capsid, said vector genome comprising a 5′ AAV inverted terminal repeat (ITR), a non-AAV nucleic acid sequence encoding a gene product operably linked to regulatory control sequences, and a 3′ AAV ITR;

(iii) a nucleic acid sequence comprising AAV rep functions and a nucleic acid sequence comprising helper functions for packaging of the vector genome into the AAVhu68 capsid;

(b) harvesting vector-containing cells and/or culture media comprising rAAVhu68 viral particles and

one or more of: concentrating the rAAVhu68 vector harvest, diafialtering the vector harvest, microfluidizing the vector harvest, nuclease digestion of the vector harvest, filtering the microfluidized intermediate, performing crude purification by chromatography, performing crude purification by ultracentrifugation, performing buffer exchange by tangential flow filtration, and/or formulation and/or filtration to prepare bulk rAAVhu68.

2 . The method according to claim 1 , wherein the method comprises concentrating the vector harvest.

3 . The method according to claim 2 , wherein the method further comprises nuclease digestion of the vector harvest.

4 . The method according to claim 2 , wherein the method further comprises performing crude purification by chromatography and/or ultracentrifugation.

5 . The method according to claim 2 , wherein the method further comprises performing tangential flow filtration.

6 . A method for separating recombinant adeno-associated virus hu68 (rAAVhu68) particles having packaged genomic sequences from genome-deficient AAVhu68 intermediates from an rAAVhu68 vector harvest comprising:

(a) culturing a packaging host cell comprising

(i) an AAVhu68 capsid nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:2 operably linked to regulatory sequences which direct expression of AAVhu68 VP1 capsid proteins, AAVhu68 VP2 capsid proteins and AAVhu68 VP3 capsid proteins, wherein said capsid proteins which assemble into an AAVhu68 capsid in the cells of the culture;

(ii) a nucleic acid molecule comprising a vector genome for packaging into the AAVhu68 capsid, said vector genome comprising a 5′ AAV inverted terminal repeat (ITR), a non-AAV nucleic acid sequence encoding a gene product operably linked to regulatory control sequences, and a 3′ AAV ITR;

(iii) a nucleic acid sequence comprising AAV rep functions and a nucleic acid sequence comprising helper functions for packaging of the vector genome into the AAVhu68 capsid;

(b) harvesting vector-containing cells and/or culture media comprising rAAVhu68 viral particles and one or more of subjecting a suspension comprising the harvested recombinant AAVhu68 viral particles and AAVhu68 capsid intermediates to fast performance liquid chromatography, equilibrating a strong anion exchange resin at a pH of 10.0 to 10.4 for binding of the AAVhu68 viral particles and AAVhu68 intermediates; subjecting the resin to a salt gradient while monitoring eluate for ultraviolet absorbance at about 260 and about 280, and/or monitoring ultraviolet absorbance of the eluate for an inflection point in a ratio of A260/A280 and, collecting the full particles from the resulting fraction.

7 . The method according to claim 6 , wherein the anion exchange resin is equilibrated at a pH of 10.2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2024
From: WILSON, JAMES M.; WANG, QIANG; GILES, APRIL; TURNER, KEVIN
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 068294/0609 →
Continuity (5)
Continuation 16487674
Provisional Application 62614002 · Jan 5, 2018
Provisional Application 62591002 · Nov 27, 2017
Provisional Application 62464748 · Feb 28, 2017
Related Publication 20240117322A1 · Apr 11, 2024
References Cited (400)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5478745A · Samulski et al. · 1995 [cited by applicant]
US 5741683A · Zhou et al. · 1998 [cited by applicant]
US 5811524A · Brams et al. · 1998 [cited by applicant]
US 5830462A · Crabtree et al. · 1998 [cited by applicant]
US 5834266A · Crabtree et al. · 1998 [cited by applicant]
US 5869337A · Crabtree et al. · 1999 [cited by applicant]
US 5871753A · Crabtree et al. · 1999 [cited by applicant]
US 6011018A · Crabtree et al. · 2000 [cited by applicant]
US 6015709A · Natesan · 2000 [cited by applicant]
US 6043082A · Crabtree et al. · 2000 [cited by applicant]
US 6046047A · Crabtree et al. · 2000 [cited by applicant]
US 6057152A · Samulski et al. · 2000 [cited by applicant]
US 6063625A · Crabtree et al. · 2000 [cited by applicant]
US 6117680A · Natesan et al. · 2000 [cited by applicant]
US 6127521A · Berlin et al. · 2000 [cited by applicant]
US 6133456A · Holt et al. · 2000 [cited by applicant]
US 6140120A · Crabtree et al. · 2000 [cited by applicant]
US 6150137A · Berlin et al. · 2000 [cited by applicant]
US 6150527A · Holt et al. · 2000 [cited by applicant]
US 6165787A · Crabtree et al. · 2000 [cited by applicant]
US 6166197A · Cook et al. · 2000 [cited by applicant]
US 6187757B1 · Clackson et al. · 2001 [cited by applicant]
US 6200560B1 · Couto et al. · 2001 [cited by applicant]
US 6204059B1 · Samulski et al. · 2001 [cited by applicant]
US 6221349B1 · Couto et al. · 2001 [cited by applicant]
US 6258603B1 · Carlson et al. · 2001 [cited by applicant]
US 6258823B1 · Holt et al. · 2001 [cited by applicant]
US 6268213B1 · Samulski et al. · 2001 [cited by applicant]
US 6326166B1 · Pomerantz et al. · 2001 [cited by applicant]
US 6464374B2 · Akiyama et al. · 2002 [cited by applicant]
US 6464974B1 · Berlin et al. · 2002 [cited by applicant]
US 6476200B1 · Sabatini et al. · 2002 [cited by applicant]
US 6479653B1 · Natesan et al. · 2002 [cited by applicant]
US 6491907B1 · Rabinowitz et al. · 2002 [cited by applicant]
US 6506379B1 · Clackson et al. · 2003 [cited by applicant]
US 6509152B1 · Berlin et al. · 2003 [cited by applicant]
US 6596535B1 · Carter · 2003 [cited by applicant]
US 6649595B2 · Clackson et al. · 2003 [cited by applicant]
US 6660514B1 · Zolotukhin et al. · 2003 [cited by applicant]
US 6693189B2 · Holt et al. · 2004 [cited by applicant]
US 6780639B1 · Chtarto et al. · 2004 [cited by applicant]
US 6951753B2 · Shenk et al. · 2005 [cited by applicant]
US 6972193B1 · Crabtree et al. · 2005 [cited by applicant]
US 6984635B1 · Schreiber et al. · 2006 [cited by applicant]
US 7008780B2 · Pomerantz et al. · 2006 [cited by applicant]
US 7045315B2 · Evans et al. · 2006 [cited by applicant]
US 7067526B1 · Yang et al. · 2006 [cited by applicant]
US 7091038B2 · Palli et al. · 2006 [cited by applicant]
US 7094604B2 · Snyder et al. · 2006 [cited by applicant]
US 7109317B1 · Clemons et al. · 2006 [cited by applicant]
US 7125717B2 · Carter · 2006 [cited by applicant]
US 7172893B2 · Rabinowitz et al. · 2007 [cited by applicant]
US 7196192B2 · Yang et al. · 2007 [cited by applicant]
US 7201898B2 · Monahan et al. · 2007 [cited by applicant]
US 7229823B2 · Samulski et al. · 2007 [cited by applicant]
US 7282199B2 · Gao et al. · 2007 [cited by applicant]
US 7439065B2 · Ferrari et al. · 2008 [cited by applicant]
US 7442373B2 · Morrow et al. · 2008 [cited by applicant]
US 7456683B2 · Takano et al. · 2008 [cited by applicant]
US 7485441B2 · Pomerantz et al. · 2009 [cited by applicant]
US 7588772B2 · Kay et al. · 2009 [cited by applicant]
US 7785888B2 · Carter · 2010 [cited by applicant]
US 7790449B2 · Gao et al. · 2010 [cited by applicant]
US 7838657B2 · Singh et al. · 2010 [cited by applicant]
US 7846729B2 · Carter · 2010 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 7985565B2 · Mayer et al. · 2011 [cited by applicant]
US 8008005B2 · Belshaw et al. · 2011 [cited by applicant]
US 8093054B2 · Carter · 2012 [cited by applicant]
US 8110560B2 · Singh et al. · 2012 [cited by applicant]
US 8114402B2 · Grandea et al. · 2012 [cited by applicant]
US 8124092B2 · Lanzavecchia · 2012 [cited by applicant]
US 8211631B2 · Svendsen et al. · 2012 [cited by applicant]
US 8361977B2 · Baker et al. · 2013 [cited by applicant]
US 8734809B2 · Gao et al. · 2014 [cited by applicant]
US 8852595B2 · Vogels et al. · 2014 [cited by applicant]
US 8927514B2 · Chatterjee et al. · 2015 [cited by applicant]
US 8961978B2 · Kwaks et al. · 2015 [cited by applicant]
US 8980853B2 · Bennett et al. · 2015 [cited by applicant]
US 9034836B2 · Dodge et al. · 2015 [cited by applicant]
US 9340603B2 · Lanzavecchia · 2016 [cited by applicant]
US 9719106B2 · Wilson et al. · 2017 [cited by applicant]
US 10265417B2 · Wilson et al. · 2019 [cited by applicant]
US 10370435B2 · Brandenburg et al. · 2019 [cited by applicant]
US 10485883B2 · Wilson et al. · 2019 [cited by applicant]
US 10695441B2 · Wilson et al. · 2020 [cited by applicant]
US 10722598B2 · Wilson et al. · 2020 [cited by applicant]
US 10786568B2 · Limberis et al. · 2020 [cited by applicant]
US 10973928B2 · Wilson et al. · 2021 [cited by applicant]
US 11827906B2 · Wilson · 2023 [cited by examiner]
US 20020110861A1 · Dhadialla et al. · 2002 [cited by applicant]
US 20020173474A1 · Schreiber et al. · 2002 [cited by applicant]
US 20040033600A1 · Palli et al. · 2004 [cited by applicant]
US 20040096942A1 · Kapitskaya et al. · 2004 [cited by applicant]
US 20050266457A1 · Palli et al. · 2005 [cited by applicant]
US 20060014711A1 · Evans et al. · 2006 [cited by applicant]
US 20060100416A1 · Palli et al. · 2006 [cited by applicant]
US 20060136184A1 · Gustafsson et al. · 2006 [cited by applicant]
US 20070036760A1 · Wilson et al. · 2007 [cited by applicant]
US 20070161086A1 · Palli et al. · 2007 [cited by applicant]
US 20090100535A1 · Pomerantz et al. · 2009 [cited by applicant]
US 20090104232A1 · Crystal et al. · 2009 [cited by applicant]
US 20090197338A1 · Vandenberghe et al. · 2009 [cited by applicant]
US 20090275107A1 · Lock et al. · 2009 [cited by applicant]
US 20100080813A1 · Lanzavecchia · 2010 [cited by applicant]
US 20110076265A1 · Burioni et al. · 2011 [cited by applicant]
US 20110150904A1 · Schiltz et al. · 2011 [cited by applicant]
US 20110236353A1 · Wilson et al. · 2011 [cited by applicant]
US 20110274702A1 · Lanzavecchia · 2011 [cited by applicant]
US 20120232133A1 · Balazs et al. · 2012 [cited by applicant]
US 20120282695A1 · Blain et al. · 2012 [cited by applicant]
US 20130045186A1 · Gao et al. · 2013 [cited by applicant]
US 20130243792A1 · Vogels et al. · 2013 [cited by applicant]
US 20140032186A1 · Gustafsson et al. · 2014 [cited by applicant]
US 20140037637A1 · McNally et al. · 2014 [cited by applicant]
US 20140065666A1 · Simpson et al. · 2014 [cited by applicant]
US 20140094392A1 · Bowers et al. · 2014 [cited by applicant]
US 20140127749A1 · Mason et al. · 2014 [cited by applicant]
US 20150344911A1 · Chatterjee et al. · 2015 [cited by applicant]
US 20160074474A1 · Passini et al. · 2016 [cited by applicant]
US 20170028082A1 · Wilson et al. · 2017 [cited by applicant]
US 20170043035A1 · Wilson et al. · 2017 [cited by applicant]
US 20170081392A1 · Wilson et al. · 2017 [cited by applicant]
US 20170101458A1 · Wilson et al. · 2017 [cited by applicant]
US 20170159027A1 · Wilson et al. · 2017 [cited by applicant]
US 20170292132A1 · Wilson et al. · 2017 [cited by applicant]
US 20180243416A1 · Limberis et al. · 2018 [cited by applicant]
US 20180353624A1 · Wilson et al. · 2018 [cited by applicant]
US 20190015527A1 · Wilson et al. · 2019 [cited by applicant]
US 20190054188A1 · Wilson et al. · 2019 [cited by applicant]
US 20190216841A1 · Wilson et al. · 2019 [cited by applicant]
US 20200056159A1 · Wilson et al. · 2020 [cited by applicant]
US 20200056205A1 · Wilson et al. · 2020 [cited by applicant]
US 20200155704A1 · Wilson et al. · 2020 [cited by applicant]
US 20200390888A1 · Limberies et al. · 2020 [cited by applicant]
US 20210170050A1 · Wilson et al. · 2021 [cited by applicant]
EP 1310571 · 2003 [cited by applicant]
EP 2296700A2 · 2011 [cited by applicant]
EP 3589730B1 · 2023 [cited by applicant]
WO WO199418347 · 1994 [cited by applicant]
WO WO199533052 · 1995 [cited by applicant]
WO WO199606097 · 1996 [cited by applicant]
WO WO1996009378 · 1996 [cited by applicant]
WO WO1996020951 · 1996 [cited by applicant]
WO WO199641865 · 1996 [cited by applicant]
WO WO199731898 · 1997 [cited by applicant]
WO WO199802441 · 1998 [cited by applicant]
WO WO199910508 · 1999 [cited by applicant]
WO WO199910510 · 1999 [cited by applicant]
WO WO199936553 · 1999 [cited by applicant]
WO WO199941258 · 1999 [cited by applicant]
WO WO2001114387 · 2001 [cited by applicant]
WO WO200170816 · 2001 [cited by applicant]
WO WO200229075 · 2002 [cited by applicant]
WO WO2002066612 · 2002 [cited by applicant]
WO WO2002066613 · 2002 [cited by applicant]
WO WO2002066614 · 2002 [cited by applicant]
WO WO2002066615 · 2002 [cited by applicant]
WO WO2003042397 · 2003 [cited by applicant]
WO WO2005033321 · 2005 [cited by applicant]
WO WO2005108617 · 2005 [cited by applicant]
WO WO2006110689 · 2006 [cited by applicant]
WO WO2007127264 · 2007 [cited by applicant]
WO WO2008156763 · 2008 [cited by applicant]
WO WO2009079259A2 · 2009 [cited by applicant]
WO WO2009115972 · 2009 [cited by applicant]
WO WO2009121004A2 · 2009 [cited by applicant]
WO WO2010010466 · 2010 [cited by applicant]
WO WO2010044921A2 · 2010 [cited by applicant]
WO WO2010053572 · 2010 [cited by applicant]
WO WO2010071832A1 · 2010 [cited by applicant]
WO WO2010130636 · 2010 [cited by applicant]
WO WO2010140114 · 2010 [cited by applicant]
WO WO2010151673 · 2010 [cited by applicant]
WO WO2011126808 · 2011 [cited by applicant]
WO WO2012145572 · 2012 [cited by applicant]
WO WO2012170930 · 2012 [cited by applicant]
WO WO2013007770 · 2013 [cited by applicant]
WO WO2013049492 · 2013 [cited by applicant]
WO WO2013049493 · 2013 [cited by applicant]
WO WO2013114885 · 2013 [cited by applicant]
WO WO2013132007 · 2013 [cited by applicant]
WO WO2013155222 · 2013 [cited by applicant]
WO WO2013182683 · 2013 [cited by applicant]
WO WO2013190059 · 2013 [cited by applicant]
WO WO2015012924 · 2015 [cited by applicant]
WO WO2015127136 · 2015 [cited by applicant]
WO WO2015164757 · 2015 [cited by applicant]
WO WO2016049230 · 2016 [cited by applicant]
WO WO2016054598 · 2016 [cited by applicant]
WO WO2016124768 · 2016 [cited by applicant]
WO WO2016200543 · 2016 [cited by applicant]
WO WO2017075119 · 2017 [cited by applicant]
WO WO2017100674 · 2017 [cited by applicant]
WO WO2017100676 · 2017 [cited by applicant]
WO WO2017100704 · 2017 [cited by applicant]
WO WO2017106244 · 2017 [cited by applicant]
WO WO2017106326 · 2017 [cited by applicant]
WO WO2017106354 · 2017 [cited by applicant]
WO WO2017136500 · 2017 [cited by applicant]
WO WO2017160360 · 2017 [cited by applicant]
WO WO2018035059 · 2018 [cited by applicant]
WO WO2018057916 · 2018 [cited by applicant]
WO WO2018160573 · 2018 [cited by applicant]
Adam VS et al., Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. Clin. Vaccine Immunol., 21(11):1528-33, Nov. 2014. (Epub Sep. 10, 2014). [cited by applicant]
Afonine PV et al., Towards automated crystallographic structure refinement with phenix.refine, Acta Crystallogr. D Biol. Crystallogr., 68(Pt 4):352-67, Apr. 2012. (Epub Mar. 16, 2012). [cited by applicant]
Alexander MC et al., Insulin stimulates glyceraldehyde-3-phosphate dehydrogenase gene expression through cis-acting DNA sequences, Proc Natl Acad Sci USA, 85(14):5092-6, Jul. 1988. [cited by applicant]
Ali MY, Histology of the Human Nasopharyngeal Mucosa, J. Anat., 99(3):657-672, 1965. [cited by applicant]
Almond B. and Schenborn ET, A Comparison of pCI-neo Vector and pcDNA4/HisMax Vector, Promega Corporation Website, Updated 2000, Available from: http://www.promega.com/resources/pubhub/enotes/a-comparison-of-pcineo-vecto… [cited by applicant]
Amara JF et al., A versatile synthetic dimerizer for the regulation of protein-protein interactions, Proc. Natl. Acad. Sci. USA, 94(20):10618-23, Sep. 1997. [cited by applicant]
An W et al., Active retrotransposition by a synthetic L1 element in mice, Proc Natl Acad Sci U S A, 103(49):18662-7, Dec. 5, 2006. (Epub Nov. 21, 2006). [cited by applicant]
Andersson R et al, An atlas of active enhancers across human cell types and tissues, Nature, 507(7493):455-61, Mar. 27, 2014. [cited by applicant]
Aquino TL et al., Influenza Outbreak in a Vaccinated Population—USS Ardent, Feb. 2014. MMWR Morb Mortal Wkly Rep, 63(42):947-9, Oct. 24, 2014. [cited by applicant]
Arkblad et al., A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatr. May 2009;98(5):865-72. Epub Jan. 20, 2009. [cited by applicant]
Armbruster et al., Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy, Molecular Therapy: Methods & Clinical De… [cited by applicant]
Arnold et al., Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. Feb. 2015;51(2):157-67. Epub Dec. 16, 2014. [cited by applicant]
Aschauer et el., Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain, PLoS One, vol. 8(9):e76310(1-16), Sep. 2013. [cited by applicant]
Ashkenazi A et al., Immunoadhesins, International reviews of immunology, 10(2):219-227, 1993. [cited by applicant]
Balazs AB et al., Antibody-based protection against HIV infection by vectored immunoprophylaxis, Nature, 481(7379):81-4, Nov. 30, 2011. [cited by applicant]
Ballay A et al., In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses, EMBO J., 4(13B):3861-5, Dec. 30, 1985. [cited by applicant]
Bankiewicz et al., Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther. Oct. 2006;14(4):564-70. Epub Jul. 7, 2006. [cited by applicant]
Bartus et al., Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy. Mol Ther. Mar. 2014; 22(3): 487-497. [cited by applicant]
Bell et al., An optimized protocol for detection of [cited by applicant]
Bell et al., Analysis of Tumors Arising in Male B6C3F1 Mice with and without AAV Vector Delivery to Liver. Mol Ther. Jul. 2006;14(1):34-44. Epub May 6, 2006. [cited by applicant]
Bell et al., Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol. Jul. 2012;86(13):7326-33. Epub Apr. 18, 2012. [cited by applicant]
Bell et al., No Evidence for Tumorigenesis of AAV Vectors in a Large-Scale Study in Mice. Mol Ther. Aug. 2005;12(2):299-306. [cited by applicant]
Bell P et al. Motor neuron transduction after intracisternal delivery of AAV9 in a cynomolgus macaque. Hum Gene Ther Methods. Apr. 2015;26(2):43-4. [cited by applicant]
Bell et al., The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest. Jun. 2011;121(6):2427-35. Epub May 16, 2011. [cited by applicant]
Bendell, et al, Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 97, 2972-2977 (2003). [cited by applicant]
Benkhelifa-Ziyyat et al., Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther. Feb. 2013;21(2):282-90. Epub Jan. 8, 2013. [cited by applicant]
Berezov A et al., Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis, J. Med. Chem., 44(16):2565-74, Aug. 2001. [cited by applicant]
Bergman et al., Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. J Pharmacol Exp Ther. Jan. 1998;284(1):111-5. [cited by applicant]
Bevan et al., Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet. Oct. 15, 2010;19(20):3895-905. Epub Jul. 16, 2010. [cited by applicant]
Beyer We et al., Cochrane re-arranged: support for policies to vaccinate elderly people against influenza, Vaccine, 31(50):6030-3, Dec. 2013. (Epub Oct. 3, 2013). [cited by applicant]
Bousquet et al., Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. J Clin Oncol. Jun. 1, 2016;34(16):e151-5. Epub Dec. 29, 2014. [cited by applicant]
Bouvier NM et al., The biology of influenza viruses, Vaccine, 26 Suppl 4:D49-53, Sep. 2008. [cited by applicant]
Boyer JL et al., 853. Persistent expression of single chain antibodies mediated by AAV5 and AAVrh. 10 vectors, Molecular Therapy, 11(Supp. 1):331-2, May 2005. [cited by applicant]
Brandenburg B et al., Mechanisms of hemagglutinin targeted influenza virus neutralization, PLoS One, 8(12):e80034(1-14), Dec. 11, 2013. [cited by applicant]
Brantly et al., Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAVI-AAT gene therapy. Proc Natl Acad Sci U S A. Sep. 22, 2009;106(38):16363-8. Epub Aug. 1, 2009. [cited by applicant]
Brinster et al., Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs, Nature, 296:39-42, Mar. 4, 1982. [cited by applicant]
Bryant et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev. Jun. 2013;24(2):55-64. Epub Jun. 29, 2013. [cited by applicant]
Bucher et al., Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Ther. May 2014;21(5):522-8. Epub Feb. 27, 2014. [cited by applicant]
Buning et al., Recent developments in adeno-associated virus vector technology, J Gene Med. Jul. 2008;10(7):717-33. [cited by applicant]
Bussaglia et al., A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. Nat Genet. Nov. 1995;11(3):335-7. [cited by applicant]
Calcedo et al., Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. Feb. 1, 2009;199(3):381-90. [cited by applicant]
Cao et al., Distance, Depth and Puncture Angle for Cisterna Magna in Chinese Adults as Read from Magnetic Resonance Imaging. Chin Med J (Engl). Jun. 20, 2015;128(12):1683-5. [cited by applicant]
Carragher B et al., Leginon: an automated system for acquisition of images from vitreous ice specimens, J. Struct. Biol., 132(1):33-45, Oct. 2000. [cited by applicant]
Carter BJ, Chapter 10: The Growth Cycle of Adeno-associated Virus, in CRC Handbook of Parvoviruses, ed. P. Tijsser, CRC Press, p. 155-68, 1990. [cited by applicant]
Castle et al., Adeno-associated virus serotypes 1, 8, and 9 share conserved mechanisms for anterograde and retrograde axonal transport. Hum Gene Ther. Aug. 2014;25(8):705-20. Epub May 2, 2014. [cited by applicant]
Castle et al., Long-distance axonal transport of AAV9 is driven by dynein and kinesin-2 and is trafficked in a highly motile Rab7-positive compartment. Mol Ther. Mar. 2014;22(3):554-566. Epub Oct. 8, 2013. [cited by applicant]
Cearley et al., Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther. Oct. 2008;16(10):1710-8. Epub Aug. 19, 2008. [cited by applicant]
Center for Disease Control and Prevention, “Types of Influenza Viruses” Web page <https://www.cdc.gov/flu/about/viruses/types.htm>, 2 pages, Apr. 4, 2016, page last updated Aug. 19, 2014, retrieved from Internet Archive… [cited by applicant]
Centers for Disease Control and Prevention, Estimates of deaths associated with seasonal influenza: United States, 1976-2007, available in MMWR Morb. Mortal. Wkly. Rep. 59:1057-1062, Aug. 27, 2010. [cited by applicant]
Chamow SM and Ashkenazi, Immunoadhesins: principles and applications, Trends in biotechnology, 14(2):52-60, Feb. 1996. [cited by applicant]
Chandler et al., Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. Feb. 2015;125(2):870-80. Epub Jan. 20, 2015. [cited by applicant]
Chen H et al., Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature, 436(7048):191-2, Jul. 14, 2005. [cited by applicant]
Chen et al., Prevalence and risk factors for feeding and swallowing difficulties in spinal muscular atrophy types II and III. J Pediatr. Mar. 2012;160(3):447-451.el. Epub Sep. 1, 2011. [cited by applicant]
Ch'ng JL et al., Antisense RNA complementary to 3′ coding and noncoding sequences of creatine kinase is a potent inhibitor of translation in vivo, Proc. Natl. Acad. Sci. USA, 86(24):10006-10, Dec. 1989. [cited by applicant]
Cho and Dreyfuss, A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev. Mar. 1, 2010;24(5):438-42. [cited by applicant]
Ciesielska et al., Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther. Jan. 2013;21(1):158-66. Epub Aug. 2, 2012. [cited by applicant]
Cobleigh, et al, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metast… [cited by applicant]
Colle et al., Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet. Jan. 1, 2010;19(1):147-58. [cited by applicant]
Coovert et al., The survival motor neuron protein in spinal muscular atrophy. Human Molecular Genetics. 1997;6(8):1205-14. [cited by applicant]
Corti D et al., A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins, Science, 333:850-6, Aug. 12, 2011. (Epub Jul. 28, 2011). [cited by applicant]
Cox F et al., Protection against H5N1 influenza virus induced by matrix-M adjuvanted seasonal virosomal vaccine in mice requires both antibodies and T cells, PLoS One, 10(12):e0145243, Dec. 22, 2015. [cited by applicant]
Crawford & Pardo. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis. Apr. 1996;3(2):97-110. [cited by applicant]
Crawford et al., Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One. 2012;7(4):e33572. Epub Apr. 27, 2012. [cited by applicant]
Crosariol M, et al., Effective AAV9 Vector Delivery to Nasal Mucosa for Protection Against Airborne Challenge With Influenza A and B, Abstract 699, Molecular Therapy, 24(Supp. 1):S276, May 2016. [cited by applicant]
Daley, J., Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals. The Scientist, Jan. 31, 2018, printed from https://www.the-scientist.com/the-nutshell/severe-toxicity-reported-in-high-dose-aav-gene-therapy-… [cited by applicant]
David et al., Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep., Hum Gene Ther. Apr. 2011;22(4):419-26. Epub Feb. 2, 2011. [cited by applicant]
Davidson E et al., Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies, 89(21):10982-92, Nov. 2015. (Epub Aug. 26, 2015). [cited by applicant]
Dawood FS et al., Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study, Lancet Infect Dis, 12(9):687-95, Sep. 2012. (Epub Jun. 26, 2012). [cited by applicant]
De BP et al., Abstract 611—Induction of Persistent Passive Immunity Against Anthrax Toxin by an Adeno-Associated Virus Type rh1O Vector Expressing Anti-Protective Antigen Antibody, Molecular Therapy, 13(Suppl. 1):S236, … [cited by applicant]
De BP et al, Rapid/ Sustained Anti-anthrax Passive Immunity Mediated by co-administration od Ad/AAV, Molecular Therapy, 6(1):203-9, Jan. 2008. [cited by applicant]
De BP et al., High levels of persistent expression of alpha 1-antitrypsin mediated by the nonhuman primate serotype rh. 10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses, Mo… [cited by applicant]
Dekaban, Changes in brain weights during the span of human life: relation of brain weights to body heights and body weights. Ann Neurol. Oct. 1978;4(4):345-56. [cited by applicant]
Delzor et al., Restricted transgene expression in the brain with cell-type specific neuronal promoters. Human Gene Therapy Methods. Hum Gene Ther Methods. Aug. 2012;23(4):242-54. Epub Aug. 30, 2012. [cited by applicant]
Deuschle U et al., Tetracycline-Reversible Silencing of Eukaryotic Promoters, Mol Cell Biol., 15(4):1907-14, Apr. 1995. [cited by applicant]
Deverman et al., Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. Feb. 2016;34(2):204-9. Epub Feb. 1, 2016. [cited by applicant]
Dhuria SV et al., Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations, Journal of Pharmaceutical Sciences, 99(4):1654-73, Apr. 2010. (Epub Oct. 29, 2009). [cited by applicant]
Didonato et al., Cloning, characterization, and copy number of the murine survival motor neuron gene: homolog of the spinal muscular atrophy-determining gene. Genome Res. Apr. 1997;7(4):339-52. [cited by applicant]
Dilillo DJ et al., Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection, J. Clin. Invest., 126(2):605-10, Feb. 2016. (Epub Jan. 5, 2016). [cited by applicant]
Dilillo DJ et al., Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo, Nat. Med., 20(2):143-51, Feb. 2014. (Epub Jan. 12, 2014). [cited by applicant]
Dimattia et al., Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol. Jun. 2012;86(12):6947-58. Epub Apr. 11, 2012. [cited by applicant]
Dirren et al., Intracerebroventricular Injection of Adeno-Associated Virus 6 and 9 Vectors for Cell Type-Specific Transgene Expression in the Spinal Cord. Hum Gene Ther. Feb. 2014;25(2):109-20. Epub Jan. 15, 2014. [cited by applicant]
Djupesland PG, Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review, Drug Deliv Transl Res, 3(1):42-62, Feb. 2013. (Epub Oct. 18, 2012). [cited by applicant]
Dominguez et al., Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. Hum Mol Genet. Feb. 15, 2011;20(4):681-93. Epub Nov. 30, 2010. [cited by applicant]
Donnelly MLL et al., The cleavage activities of aphthovirus and cardiovirus 2A proteins, J. Gen. Virol., 78(Pt 1):13-21, Jan. 1997. [cited by applicant]
Donsante et al., Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. Sep. 2001;8(17):1343-6. [cited by applicant]
Dreyfus C et al., Highly conserved protective epitopes on influenza B viruses, Science, 337:1343-8, Sep. 14, 2012. (Epub Aug. 9, 2012). [cited by applicant]
Dul et al., Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses… [cited by applicant]
Dubowitz, Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol. 1999;3(2):49-51. [cited by applicant]
Duque et al., A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol. Mar. 2015;77(3):399-414. Epub Feb. 9, 2015. [cited by applicant]
Duque et al., Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther. Jul. 2009;17(7):1187-96. Epub Apr. 14, 2009. [cited by applicant]
Ekiert DC et al., A highly conserved neutralizing epitope on group 2 influenza A viruses, Science, 333(6044):843-50, Aug. 12, 2011. (Epub Jul. 7, 2011). [cited by applicant]
Ekiert DC et al., Antibody recognition of a highly conserved influenza virus epitope, Science, 324(5924):246-51, Apr. 10, 2009. (Epub Feb. 26, 2009). [cited by applicant]
Ekiert DC et al., Cross-neutralization of influenza A viruses mediated by a single antibody loop, Nature, 489(7417):526-32, Sep. 27, 2012. (Epub Sep. 16, 2012). [cited by applicant]
El-Khodor et al., Identification of a battery of tests for drug candidate evaluation in the SMNΔ7 neonate model of spinal muscular atrophy. Exp Neurol. Jul. 2008;212(1):29-43. Epub Mar. 18, 2008. [cited by applicant]
Ellinwood et al. Safe, Efficient, and Reproducible Gene Therapy of the Brain in the Dog Models of Sanfilippo and Hurler Syndromes. Mol Ther. Feb. 2011;19(2):251-259. [cited by applicant]
Emsley P et al., Cowtan, Features and development of Coot, Acta Crystallogr. D Biol. Crystallogr., 66(Pt 4):486-501, Apr. 2010. (Epub Mar. 24, 2010). [cited by applicant]
Ercolani L et al., Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene, J Biol Chem, 263(30):15335-41, Oct. 25, 1988. [cited by applicant]
European Medicines Agency, Guideline on Development, Production, Characterisation and Specifications for Monoclonal Antibodies and Related Products (EMEA/CHMP/BWP/157653/2007), published Dec. 2008. [cited by applicant]
European Medicines Agency, Guideline on Development, Production, Characterization and Specifications for Monoclonal Antibodies and Related Products (EMEA/CHMP/BWP/532517/2008), p. 1-13, published Dec. 2008. [cited by applicant]
Fang J et al., An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo, Mol. Ther., 15(6);1153-9, Jun. 2007. (Epub Mar. 20, 2007). [cited by applicant]
Fang et al. Molecular characterization and copy No. of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls. BMC Musculoskelet Disord. 2015; 16(1): 11. [cited by applicant]
Faravelli, et al. Spinal muscular atrophy—recent therapeutic advances for an old challenge. Nat Rev Neurol. Jun. 2015;11(6):351-9. Epub May 19, 2015. [cited by applicant]
Federici et al., Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. Aug. 2012;19(8):852-9. Epub Sep. 15, 2011. [cited by applicant]
Feldkotter et al., Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. Feb. 2002;70(… [cited by applicant]
Finkel et al. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy Nov. 7-9, 2014, Heemskerk, The Netherlands. Neuromuscul Disord. Jul. 2015;25(7):593-602. Epub Apr… [cited by applicant]
Finkel et al., Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. Nov. 2, 2017;377(18):1723-1732. [cited by applicant]
Finkel et al., Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. Aug. 26, 2014;83(9):810-7. Epub Jul. 30, 2014. [cited by applicant]
Finkel, Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I. Neuromuscul Disord. Feb. 2013;23(2):112-5. Epub Nov. 10, 2012. [cited by applicant]
Fisher et al., Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol. Jan. 1996;70(1):520-32. [cited by applicant]
Flotte TR et al., Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A. 90(22):10613-7, Nov. 15, 1993. [cited by applicant]
Flotte and Buning, Severe Toxicity in Nonhuman Primates and Piglets with Systemic High-Dose Administration of Adeno-Associated Virus Serotype 9-Like Vectors: Putting Patients First. Hum Gene Ther. Mar. 2018;29(3):283-28… [cited by applicant]
Forsman A et al., Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J. Virol., 82(24):12069-81, Dec. 2008. (Epub Oct. 8, 2… [cited by applicant]
Foster et al., Codon and mRNA sequence optimization for microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther. 2008; 16:1825-32 and Sup… [cited by applicant]
Foust et al., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat Biotechnol. Jan. 2009;27(1):59-65. Epub Dec. 21, 2008. [cited by applicant]
Friedmann, Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing. Gene Ther. Sep. 2017;24(9):503-505. Epub Jun. 22, 2017. [cited by applicant]
Friesen RH et al., A common solution to group 2 influenza virus neutralization. Proc. Natl. Acad. Sci. U.S.A., vol. 111(1):445-50, Jan. 7, 2014. (Epub Dec. 11, 2013). [cited by applicant]
Furler S et al., Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons, Gene Ther., 8(11):864-73,… [cited by applicant]
Gamblin SJ et al., Influenza hemagglutinin and neuraminidase membrane glycoproteins, Journal of Biological Chemistry, 285(37):28403-9, Sep. 10, 2010. (Epub Jun. 10, 2010). [cited by applicant]
Gao R et al., Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med., 368:1888-97, May 16, 2013. (Epub Apr. 11, 2013). [cited by applicant]
Gao et al., Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A. May 13, 2003;100(10):6081-6. Epub Apr. 25, 2003. [cited by applicant]
Gao et al., Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol. Jun. 2004;78(12):6381-8. [cited by applicant]
Gao et al., Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. Sep. 3, 2002;99(18):11854-9. Epub Aug. 21, 2002. [cited by applicant]
Gao et al., Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther. Oct. 10, 2000;11(15):2079-91. [cited by applicant]
Garcia et al., Peripheral motor and sensory nerve conduction studies in normal infants and children. Clin Neurophysiol. Mar. 2000;111(3):513-20. [cited by applicant]
GenBank Accession AAS99264.1, capsid protein VP1 [Adeno-associated virus 9, Jun. 2004. [cited by applicant]
GenBank: AAB86861.1, Web page <https://www.ncbi.nlm.nih.gov/protein/AAB86861.1>, 1 page, retrieved from Internet on May 11, 2018. [cited by applicant]
GenBank: ACJ71709.1, Web page <https://www.ncbi.nlm.nih.gov/protein/ACJ71709.1>, 2 pages, retrieved from Internet on May 11, 2018. [cited by applicant]
GenBank: AEL31303.1, Web page <https://www.ncbi.nlm.nih.gov/protein/AEL31303.1>, 2 pages, retrieved from Internet on May 11, 2018. [cited by applicant]
GenBank: AFP87542.1, Web page <https://www.ncbi.nlm.nih.gov/protein/AFP87542.1>, 2 pages, retrieved from Internet on May 11, 2018. [cited by applicant]
GenBank: AGH70219.1, Web page <https://www.ncbi.nlm.nih.gov/protein/AGH70219.1>, 1 page, retrieved from Internet on May 11, 2018. [cited by applicant]
GenBank Accession AY530553.1, Adeno-associated virus isolate pi. 1 capsid protein VP1 (cap) gene, complete cds, Jun. 2004. [cited by applicant]
GenBank: BAF64540.1, Web page <https://www.ncbi.nlm.nih.gov/protein/BAF64540.1>, 2 pages, retrieved from Internet on May 11, 2018. [cited by applicant]
GenBank: CAA24362.1, Web page <https://www.ncbi.nlm.nih.gov/protein/AGH70219.1>, 1 page, retrieved from Internet on May 11, 2018. [cited by applicant]
GenBank Accession K03104.1, Human cytomegalovirus major immediate-early gene, enhancer, Aug. 1993. [cited by applicant]
GenBank Accession NC_001401.2, Adeno-associated virus—2, complete genome, Dec. 2014. [cited by applicant]
GenBank Accession NM_000344.3, [cited by applicant]
GenBank Accession NM_001297715.1, [cited by applicant]
GenBank Accession NM_022874.2, [cited by applicant]
GenBank Accession NP 000335.1, survival motor neuron protein isoform d [cited by applicant]
GenBank Accession NP 001284644.1, survival motor neuron protein isoform a [ [cited by applicant]
GenBank: V00882.1, Web page <https://www.ncbi.nlm.nih.gov/protein/AGH70219.1>, 2 pages, retrieved from Internet on May 11, 2018. [cited by applicant]
GenBank Accession X00182.1, Gallus gallus cytoplasmic beta-actin gene, Nov. 2006. [cited by applicant]
George et al., Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. Dec. 7, 2017;377(23):2215-2227. [cited by applicant]
Giles et al., Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function. Mol Ther. Dec. 5, 2018;26(12):2848-2862. Epub Oct. 18, 2018. [cited by applicant]
Gil-Farina et al., Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients. Mol Ther. Jun. 2016;24(6):1100-1105. Epub Mar. 7, 2016. [cited by applicant]
Glaven RH et al., Linking Single Domain Antibodies that Recognize Different Epitopes on the Same Target, Biosensors (Basel), 2(1):43-56, Feb. 1, 2012. [cited by applicant]
Glezen WP et al., The burden of influenza B: a structured literature review, Am J Public Health, 103(3):e43-51, Mar. 2013. (Epub Jan. 17, 2013). [cited by applicant]
Gordeeva et al., Improved PCR-based gene synthesis method and its application to the Citrobacter freundii phytase gene codon modification. J Microbiol Methods. May 2010;81(2):147-52. Epub Mar. 10, 2010. [cited by applicant]
Gossen M and Bujard H, Tight control of gene expression in mammalian cells by tetracycline-responsive promoters, Proc. Natl. Acad. Sci. USA, 89:5547-51, Jun. 1992. [cited by applicant]
Gossen M et al., Transcriptional activation by tetracyclines in mammalian cells, Science 268(5218):1766-9, Jun. 23, 1995. [cited by applicant]
Graham et al., Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. Jul. 1977;36(1):59-74. [cited by applicant]
Gray et al., Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. Apr. 2013;20(4):450-9. Epub Jan. 10, 2013. [cited by applicant]
Gray et al., Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther. Jun. 2011;19(6):1058-69. Epub Apr. 12, 2011. [cited by applicant]
Gregoretti et al., Survival of patients with spinal muscular atrophy type 1. Pediatrics. May 2013;131(5):e1509-14. Epub Apr. 22, 2013. [cited by applicant]
Greig et al., Intramuscular Injection of AAV8 in Mice and Macaques Is Associated with Substantial Hepatic Targeting and Transgene Expression, PLoS One. Nov. 13, 2014;9(11):e112268. doi: 10.1371/journal.pone.0112268. eCo… [cited by applicant]
Grieger & Samulski, Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications, Adv. Biochem. Engin/Biotechnol. 2005;99: 119-145. [cited by applicant]
Grimm et al., Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. Jul. 1999;6(7):1322-30. [cited by applicant]
Gupta P, Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A, Mabs… [cited by applicant]
Gurda et al., Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Mol Ther. Feb. 2016;24(2):206-216. Epub Oct. 8, 2015. [cited by applicant]
Haaker and Fujak, Proximal spinal muscular atrophy: current orthopedic perspective. Appl Clin Genet. Nov. 14, 2013;6(11):113-20. [cited by applicant]
Harris A et al., Influenza virus pleiomorphy characterized by cryoelectron tomograph, Proc. Natl. Acad. Sci. U.S.A., 103(50)19123-7, Dec. 12, 2006. (Epub Dec. 4, 2006). [cited by applicant]
Helmken et al., Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet. Dec. 2003;114(1):11-21. Epub Oct. 1, 2003. [cited by applicant]
Hessell AJ et al., Fc receptor but not complement binding is important in antibody protection against HIV, Nature, 449(7158):101-104, Sep. 6, 2007. [cited by applicant]
Hinderer et al., Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates. Mol Ther. Aug. 2015; 23(8):1298-1307. Prepublished online May 29, 2015. Published online Jun. 30, 2015. [cited by applicant]
Hinderer et al., Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Mol Ther Methods Clin Dev. Dec. 10, 2014;1:14051. [cited by applicant]
Hinderer et al., Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model. Mol Genet Metab. Sep. 2016;119(1-2):124-30. Epub Jun. 8, 2016. [cited by applicant]
Hinderer, et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther. Dec. 2014;22(12):2018-27. Epub Jul. 16, 2014. [cited by applicant]
Hinderer, et al. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice. Hum Gene Ther. Nov. 2016;27(11):906-915. Epub Aug. … [cited by applicant]
Hinderer, et al. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.Hum Gene Ther. Mar. 2018;29(3):285-298. Epub Feb.… [cited by applicant]
Hioki et al., Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters. Gene Ther. Jun. 2007;14(11):872-82. Epub Mar. 15, 2007. [cited by applicant]
Hohn M et al., SPARX, a new environment for Cryo-EM image processing, J. Struct. Biol., 157(1):47-55, Jan. 2007. (Epub Jul. 16, 2006). [cited by applicant]
Holehonnur et al., Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala. BMC Neurosci. Feb. 18, 2014;15:28. [cited by applicant]
Hoogenboom HR et al., By-passing immunisation: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J. Mil. Biol., 227(2):381-8, Sep. 1992. [cited by applicant]
Hordeaux et al., The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther. Mar. 7, 2018;26(3):664-668. Epub Feb. 2, 2018. [cited by applicant]
Hu et al., RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J Gene Med. Sep. 2010;12(9):766-78. [cited by applicant]
Hua et al., Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet. Apr. 2008;82(4):834-48. Epub Mar. 27, 2008. [cited by applicant]
Hua et al., Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. Oct. 5, 2011;478(7367):123-6. [cited by applicant]
Hufton SE et al. The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency, PLoS One, vol. 9(8):e103294(1-19), Aug. 1, 2014. [cited by applicant]
Hultberg A et al., Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules, PLoS One vol. 6(4):e17665(1-12), Apr. 1, 2011. [cited by applicant]
Hynes et al., Hormone-responsive expression of an endogenous proviral gene of mouse mammary tumor virus after molecular cloning and gene transfer into cultured cells, Proc. Natl. Acad. Sci. USA, 78(4):2038-42, Apr. 1981. [cited by applicant]
Iliff et al., A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. Aug. 15, 2012;4(147):147ra111. [cited by applicant]
Iliff et al., Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci. Nov. 13, 2013;33(46):18190-9. [cited by applicant]
Invivogen, IgG-Fc Engineering for Therapeutic Use, available online at www.invivogen.com/docs/Insight200605.pdf, p. 1-4, Apr./May 2006. [cited by applicant]
Irani V et al., Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases, Molecular immunology, 67(2):171-82, Oct. 2015. (Epub Apr. … [cited by applicant]
Israel DI and Kaufman RJ, Highly inducible expression from vectors containing multiple GRE's in CHO cells overexpressing the glucocorticoid receptor, Nucl. Acids Res., 17(12):2589-2604, Nov. 12, 1989. [cited by applicant]
James et al., Predictors of outcome after acetaminophen poisoning in children and adolescents. J Pediatr. May 2002;140(5):522-6. [cited by applicant]
Janson, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther. Jul. 20, 2002;13(11):1391-412. [cited by applicant]
Jedrzejowska et al., Incidence of spinal muscular atrophy in Poland—more frequent than predicted? Neuroepidemiology. 2010;34(3):152-7. Epub Jan. 15, 2010. [cited by applicant]
Jegaskanda PC et al., Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine, J. Immunol. 193(2):469-75, Jul. 15, 2014. [cited by applicant]
Jin et al., Direct Liquid Chromatography/Mass Spectrometry Analysis for Complete Characterization of Recombinant Adeno-Associated Virus Capsid Proteins. Hum Gene Ther Methods. Oct. 2017;28(5):255-267. Epub Jun. 16, 2017. [cited by applicant]
Johnson PR et al., Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys, Nat Med., 15(8):901-6, Aug. 2009. (Epub May 17, 2009). [cited by applicant]
Jones PT et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321(6069):522-5, May 1986. [cited by applicant]
Julien JP et al., Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA, Immunol. Rev., 250(1):180-98, Nov. 2012. [cited by applicant]
Juno J et al., Immunogenetic Factors Associated with Severe Respiratory Illness Caused by Zoonotic H1N1 and H5N1 Influenza Viruses, Clinical and Developmental Immunology, vol. 2012:797180(1-9), (Epub Nov. 3, 2011). [cited by applicant]